Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Acute Kidney Injury

Therapeutic area intelligence for Acute Kidney Injury with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Companies
1

Companies

Serpin Pharma, LLC →

Assets

Amino →
SP16 →

Recent signals(2)

ClinicalJune 25, 2026

Amino Acid Infusion Shows No Benefit for AKI Post-Aortic Surgery, Subgroup Suggests Potential in Older Patients

A multicenter study found no significant benefit of amino acid infusion on AKI incidence post-aortic surgery, though older patients showed a potential lower risk.

ClinicalJune 23, 2026

SP16 Trial Aims to Prevent Acute Kidney Injury in CKD Patients Undergoing Cardiac Surgery

A clinical trial is underway to evaluate the efficacy and safety of SP16 in preventing acute kidney injury in patients with chronic kidney disease undergoing cardiac surgery.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.